Ocular manifestations of Monkeypox virus (MPXV) infection with viral persistence in ocular samples: A case series
Luciana Peixoto Finamor, Maria Cássia Mendes-Corrêa, Mônica Rinkevicius, Guilherme Macedo, Éster Cerdeira Sabino, Lucy Santos Villas-Boas, Anderson Vicente de Paula, Raissa Heloisa de Araujo-Heliodoro, Antônio Charlys da Costa, Steven S. Witkin, Keila Lima Carneiro Santos, Camila Palmeira, Gabriel Costa de Andrade, Maurílio Lucena, Dalton de Freitas Santoro, Luci Meire Pereira da Silva, Cristina Muccioli
Abstract
OBJECTIVE: We describe the clinical presentation and ocular viral dynamics in patients with Monkeypox virus-related ophthalmic disease (MPXROD). METHODS: In this case series, we investigated five consecutive patients with confirmed mpox, diagnosed through a positive Monkeypox virus (MPXV) Polymerase Chain Reaction (PCR) test and presenting with ocular symptoms. They were referred from the Reference Center for Sexually Transmitted Infections in São Paulo (CRT) to the Uveitis Sector at the Federal University of São Paulo, between August and December 2022. We performed PCR testing on ocular samples and culture supernatants for MPXV in all patients. Viral sequencing was conducted in one of the cases. RESULTS: Replicating MPXV was identified in at least one ocular sample of all patients, between day 31 and day 145 after the onset of skin lesions. All patients presented with keratitis, 3 with uveitis (60%) and two exhibited hypopyon (40%). The onset of ocular symptoms occurred at a mean of 21.2 days after the appearance of the first skin lesion and persisted, on average, for 61,.6 days, with a worsening trend observed until the initiation of tecovirimat treatment. Tecovirimat treatment was administered to all patients, with initiation occurring between 31 and 145 days after the onset of skin lesions. MPXV genome sequencing of an isolate from one patient classified it as belonging to lineage B1 in clade IIb. CONCLUSION: This study reveals a late onset and persistence of sight threatening ocular disease, along with potential viral infectivity even after systemic resolution in mpox cases. These findings highlight the risk of ongoing transmission from individuals with prolonged ocular manifestations, particularly through ocular discharge.